Eli Lilly and Company

Paul J Hoogestraat

Albert Kudzovi Amegadzie

Winton Dennis Jones, Jr

Daryl Lynn Smith

Kevin Matthew Gardinier

Jennifer Rebecca Allen

George Stuart Gregory

Stephen A Hitchcock

Thomas Edward Mabry

Michael Gregory Bell

Ana Maria Escribano

Quanrong Shen

Steven Andrew Hitchcock

Winton Dennis Junior Jones

The present invention provides aldosterone synthase inhibitors of the formula: intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.

Aldosterone synthase inhibitor

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. 

CB1 modulator compounds

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith 

CB1 antagonist compounds

Growing community of inventors

Indianapolis, IN, United States of America

Paul J Hoogestraat